135832-53-0

Upstream product

• 135832-52-9 3-(5-chloro-2-fluorophenyl)propionic acid 
• 1093173-19-3 3-(5-chloro-2-fluorophenyl)-2-propyne-1-ol 
• 71916-91-1 5-chloro-2-fluorobenzyl bromide 
• 135865-35-9 diethyl (5-chloro-2-fluorobenzyl)malonate 
• 452-66-4 5-chloro-2-fluorotoluene 

Downstream Products

• 1093173-20-6 1-(3-bromopropyl)-5-chloro-2-fluorobenzene 
• 135832-55-2 4-(3-acetoxypropyl)-2-chloro-5-fluorobenzenesulfonamide 
• 135832-56-3 4-(3-acetoxypropyl)-3-fluorobenzenesulfonamide 
• 135832-57-4 4-(3-hydroxypropyl)-3-fluorobenzenesulfonamide 
• 135832-54-1 3-(5-chloro-2-fluorophenyl)propyl acetate 

Relevant academic research and scientific papers

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

Topically active carbonic anhydrase inhibitors. 4. [(hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamides

For several decades a tantalizing goal for the treatment of primary open-angle glaucoma has been the development of a topically active carbonic anhydrase inhibitor. Recent results from several research groups indicate that considerable progress has been made toward this objective. In this report, we present the design and synthesis of (hydroxyalkyl)sulfonyl-substituted benzene- and thiophenesulfonamides. These compounds exhibit inhibition of carbonic anhydrase II in the nanomolar range and lower intraocular pressure in the α-chymotrypsinized rabbit model of ocular hypertension after topical instillation.